Literature DB >> 8419185

Cytokine regulation of the interleukin-1 receptor antagonist protein in U937 cells.

A E Berger1, D B Carter, S O Hankey, R N McEwan.   

Abstract

A naturally occurring receptor-level antagonist of interleukin-1 (IRAP or IL-1 ra) has recently been cloned. To determine what stimuli might regulate this inhibitor, cytokines were tested for their effects on the steady-state level of IRAP mRNA in phorbol ester-differentiated U937 cells. The cytokines tested fell into one of three groups: (a) inducers: granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4, (b) weak inducers (< 2-fold stimulation): [IL-1 alpha, IL-1 beta, and transforming growth factor-beta (TGF-beta)] and (c) cytokines with no effect: (IL-2, platelet-derived growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, granulocyte colony-stimulating factor, IL-3, IL-5, IL-6, interferon-gamma, multi-colony stimulating factor, tumor necrosis factor-alpha and IRAP itself. One hundred U/ml of either GM-CSF or IL-4 was the dose inducing peak IRAP mRNA expression; that peak expression occurred 12 h after addition of cytokine. GM-CSF induced a 34 +/- 15-fold increase in IRAP mRNA, and IL-4 induced a 15 +/- 6-fold increase. In the same RNA samples, GM-CSF increased IL-1 beta mRNA 5.9 +/- 1.7-fold, but IL-4 decreased IL-1 beta mRNA to half that of control levels (0.45 +/- 0.17). Thus, a single stimulus (IL-4) decreased the expression of an agonist (IL-1) while it increased the expression of an antagonist (IRAP). When U937 cells were treated with both IL-4 and GM-CSF, the level of IRAP mRNA induced was additive, suggesting that the cytokines acted differently to increase IRAP mRNA levels. The level of IL-1 mRNA in cells treated with both IL-4 and GM-CSF was intermediate. Dexamethasone and cycloheximide inhibited all mRNA increases and did not reverse IL-4-induced decreases in IL-1 mRNA. These studies have identified two cytokines which induce IRAP in the monocytic cells studied, and have partially characterized the differential regulation of IL-1 and its antagonist, IRAP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419185     DOI: 10.1002/eji.1830230108

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  Novel production of interleukin-1 receptor antagonist peptides in normal human cornea.

Authors:  M C Kennedy; J T Rosenbaum; J Brown; S R Planck; X Huang; C A Armstrong; J C Ansel
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

2.  Modulation of the IL-1 cytokine network in keratinocytes by intracellular IL-1 alpha and IL-1 receptor antagonist.

Authors:  W G Phillips; M Feldmann; S M Breathnach; F M Brennan
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

3.  Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level.

Authors:  J E García; A M López; M R de Cabo; F M Rodríguez; J P Losada; R G Sarmiento; A J López; J L Arellano
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

4.  Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Authors:  K L Mahon; H-M Lin; L Castillo; B Y Lee; M Lee-Ng; M D Chatfield; K Chiam; S N Breit; D A Brown; M P Molloy; G M Marx; N Pavlakis; M J Boyer; M R Stockler; R J Daly; S M Henshall; L G Horvath
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.